Nasal delivery of epitope based vaccines

Advanced Drug Delivery Reviews

Volumn 51, Issue 1-3, 2001, Pages 161-171

  Olszewska, Wieslawa ^a   Steward, Michael W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cowpea mosaic virus; Measles; Mimotope; Mucosa; Mucosal adjuvant; Multiple antigenic peptide; Recombinant vaccine; Synthetic peptide

Indexed keywords

DNA; IMMUNIZATION; VIRUSES;

PATHOGENS;

VACCINES;

CHIMERIC PROTEIN; CHOLERA TOXIN B SUBUNIT; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; HEAT LABILE TOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; ISCOM; MAJOR HISTOCOMPATIBILITY ANTIGEN; MATERNAL ANTIBODY; MEASLES VIRUS FUSION PROTEIN; NUCLEOPROTEIN F NP9; RECOMBINANT DNA; RESPIRATORY SYNCYTIAL VIRUS PROTEIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; B LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELLULAR IMMUNITY; HEALTH HAZARD; IMMUNIZATION; IMMUNOGENICITY; MOSAIC VIRUS; MUCOSA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN CELL; T LYMPHOCYTE; VIRUS INFECTION; VIRUS LOAD; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; EPITOPES; HUMANS; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0035940315     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00164-8     Document Type: Review

References (57)

1. Identification of two promiscuous T-cell epitopes from tetanus toxin
2. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans
3. Nasal delivery of vaccines
4. Lack of age-associated immune dysfunction in mucosal-associated lymph nodes
5. New strategies for using mucosal vaccination to achieve more effective immunisation
6. Mucosal immune response to an HIV C4/V3 peptide following nasal or interstinal immunization of rabbits
7. The effects of a flanking sequence on the immune response to a B and a T cell epitope from the fusion protein of measles virus
8. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides
9. Protection against morbillivirus-induced encephalitis by immunisation with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus
10. Immunological analysis of the protective responses to the chimeric synthetic peptide representing T- and B-cell epitopes from the fusion protein of measles virus
11. Protection against measles virus- induced encephalitis by anti-mimotope antibodies: The role of antibody affinity
12. Immune responses and protection induced by mucosal and systemic immunisation with recombinant measles nucleoprotein in a mouse model of measles-induced encephalitis
13. Induction of systemic immune responses to measles virus synthetic peptides administered intranasally
14. Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen
15. Cytotoxic T lymphocyte responses against measles virus
16. Priming of measles virus-specific CTL responses after immunisation with a CTL epitope linked to a fusogenic peptide
17. Analysis of the contribution of CTL epitopes in the immunobiology of morbillivirus infection
18. Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones
19. Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein
20. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T lymphocyte responses with non-replicating antigens
21. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunisation with a synthetic peptide
22. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunisation
23. Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide
24. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries
25. A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera
26. Induction of humoral immune response against Plasmodium falciparum sporozoites by immunisation with a synthetic peptide mimotope whose sequence was derived from screening a filamentous phage epitope library
27. Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein
28. Isolation of peptides that mimic epitopes on a malarial antigen from random peptide libraries displayed on phage
29. A mimotope from a solid-phase peptide library induces a measles virus-neutralizing and protective antibody response
30. The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: Implications for the identification of peptide mimotopes
31. Exploring immunological specificity using synthetic peptide combinatorial libraries
32. Vaccine engineering: Enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes
33. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system
34. The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases
35. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes
36. Macromolecular assemblage in the design of a synthetic AIDS vaccine
37. A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years
38. Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses
39. Anti-peptide antibody responses following intranasal immunisation: Effectiveness of mucosal adjuvants
40. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi
41. Measles virus nucleocapsid protein protects rats from encephalitis
42. NYVAC-Pf7: A poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
43. A multivalent minigene vaccine, containing B -cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen
44. Induction of genital immunity by DNA priming and intranasal booster immunisation with a replication-defective adenoviral recombinant
45. Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies
46. Potential of chimaeric plant virus particles as novel, stable vaccines
47. Expression of an animal virus antigenic site on the surface of a plant virus particle
48. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus
49. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunised with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus
50. Expression of an animal virus antigenic site on the surface of a plant virus particle
51. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope
52. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides
53. The development of cowpea mosaic virus as a potential source of novel vaccines
54. Plant-derived vaccine protects target animals against a viral disease
55. Intranasal immunisation with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunisation
56. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice
57. Successful immunisation of children with and without maternal antibody by aerosolised measles vaccine. 1. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines